Lead Product(s) : Proxalutamide,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment
Details : Clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated a positive trend.
Product Name : GT0918
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Proxalutamide,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Institut Pasteur Shanghai
Deal Size : Undisclosed
Deal Type : Partnership
Details : According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engine...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Institut Pasteur Shanghai
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : S-Trimer
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate
Details : Clover is the first company in the world to disclose a 2019-nCoV vaccine candidate that can successfully be recognized by antibodies produced by previously-infected patients.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : S-Trimer
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Proxalutamide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Applied Biology
Deal Size : Undisclosed
Deal Type : Collaboration
Applied Biology and Kintor to Collaborate on the Use of Proxalutamide for the Treatment of COVID-19
Details : The clinical study is a randomized controlled study of an anti-androgen (5-alpha reductase inhibitor) as a treatment for mildly symptomatic COVID-19 patients. The companies have teamed but to evaluate efficacy and safety of Proxalutamide.
Product Name : GT0918
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 14, 2020
Lead Product(s) : Proxalutamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Applied Biology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Shanghai Henlius Biotech
Deal Size : $3.5 million
Deal Type : Agreement
Details : Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
June 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Shanghai Henlius Biotech
Deal Size : $3.5 million
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : GeoVax Labs
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : GeoVax Labs
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : JS016
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Agreement
Junshi, Eli Lilly Agree to Co-develop JS016 Antibodies Against COVID-19
Details : Junshi Biosciences and Lilly aim to submit an IND application and initiate clinical studies in the U.S. in the second quarter of the year.
Product Name : JS016
Product Type : Antibody
Upfront Cash : Undisclosed
April 05, 2020
Lead Product(s) : JS016
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : ACE-MAB
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Sorrento Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets.
Product Name : ACE-MAB
Product Type : Antibody
Upfront Cash : Undisclosed
March 24, 2020
Lead Product(s) : ACE-MAB
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Sorrento Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Favipiravir alleviated the pneumonia symptom of COVID-19 patients with high tolerance and few adverse reactions, potentially through a mechanism that can quickly eliminate the coronaviruses.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, the companies will work together on the clinical development, manufacturing, and commercialization of Vir's proprietary antibodies.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Vir Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration